Skip to main content
Premium Trial:

Request an Annual Quote

Bruker, Closing Roentec and Princeton Gamma-Tech Acquisitions, Builds Microanalysis Unit

NEW YORK, Nov. 16 (GenomeWeb News) - Bruker AXS yesterday closed its previosuly announced acquisition of Roentec and Princeton Gamma-Tech, and has formed a new microanalysis business unit, Bruker AXS Microanalysis.


Financial details of the transactions remain undisclosed.


Bruker said the intent of the acquisitions and the formation of the new unit is to stake a place in the "$150 million" X-ray microanalysis market. Both Roentec and PGT specialize in X-ray detector instruments.


In addition, Bruker's new unit will retain members of the acquired companies' management teams. Roentec's Thomas Schuelein has been named vice president for microanalysis and PGT's Douglas Skinner has been appointed assistant vice president of the new unit, Bruker said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.